Cooley M&A

JANUARY 22, 2025

While global M&A deal value across sectors remained relatively flat overall , pharmaceuticals and life sciences M&A in 2024 dipped relative to the prior year. Indeed, the largest US biotech exit in 2024 was Vertex Pharmaceuticals $4.9 Immunology deals stood out, including Vertex Pharmaceuticals $4.9 from 2023. [1]

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

Cooley M&A

OCTOBER 19, 2022

The rise of founder-led, venture capital-backed companies in recent years has coincided with a surge of companies implementing dual-class share structures in connection with their initial public offerings. Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals. Notable public deals.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

M&A Leadership Council

AUGUST 15, 2022

For example, in Switzerland, Sandoz and Ciba spun off their chemicals business units – one as a taxable initial public offering and one as a tax-free “demerger” – before merging their pharmaceutical cores into Novartis. Sometimes spin-offs precede mergers.

Mergers and Acquisitions 40

Mergers and Acquisitions IPO M&A Initial Public Offering 40

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Moving into Q2 of 2023, roughly 29% of US public biotech companies traded below their cash value. Why did life sciences outperform the market?

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 30, 2024

Vulnerable M&A deals up for a vote Since 2022, a number of public company stockholders have launched aggressive campaigns against pending M&A deals, including at Coupa Software, Avalara, Zendesk, POINT Biopharma, Taro Pharmaceutical and Abcam.

Private Equity 52

Private Equity M&A Capital Investors 52